RxDoctor Payments Data

Andrea Irwin, APRN

Family · Bardstown, KYNPI 1508284845

Payments from drug & device makers

$1,190in general payments, 2019–2025

Across 67 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$247
  • AbbVie$212
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$139
  • Novo Nordisk$128
  • GSK$111
  • Axsome Therapeutics, Inc.$67
  • plus $287 from 11 others

What the payments were for

  • Food & beverage$1,190100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,190 in reported general payments places this provider in the 65th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$74,944
Medicare patients
225
Services billed
1,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide145$170,407
EliquisApixaban142$142,379
TrulicityDulaglutide78$119,535
JardianceEmpagliflozin99$91,728
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$91,028
JanuviaSitagliptin Phosphate60$57,478
XareltoRivaroxaban34$47,504
RybelsusSemaglutide16$28,335
FarxigaDapagliflozin Propanediol16$23,890
VraylarCariprazine Hcl14$20,269
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$18,399
Tresiba Flextouch U-200Insulin Degludec13$15,029
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$14,331
Janumet XrSitagliptin Phos/Metformin Hcl11$13,765
MounjaroTirzepatide11$13,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$128$198,742161 claims
PfizerEliquis$247$142,379142 claims
Lilly USA, LLCTrulicity, Mounjaro$65$133,14689 claims
GSKTrelegy Ellipta, Breo Ellipta$111$100,675137 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$17$35,98147 claims
AbbVieVraylar, Synthroid$212$22,37086 claims
Astellas Pharma US IncMyrbetriq$17$10,02413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,374 family providers in Kentucky.

Other family in Bardstown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →